The report "Cardiovascular Devices Market by Product (Cardiac Imaging, Rhythm Management, Cardiac Assist Devices, Interventional Cardiology, Electrophysiology, Monitoring ), Indication (CAD, MI, CHF), End User (Hospitals & Clinics) - Global Forecast to 2029", is USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, at a CAGR of 7.3% during the forecast period.

Browse 459 market data Tables and 57 Figures spread through 428 Pages and in-depth TOC on "Cardiovascular Devices Market by Product (Cardiac Imaging, Rhythm Management, Cardiac Assist Devices, Interventional Cardiology, Electrophysiology, Monitoring ), Indication (CAD, MI, CHF), End User (Hospitals & Clinics) - Global Forecast to 2029"

Download PDF- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=72205881

The cardiovascular devices market is growth-driven by a few factors, which include the high prevalence of cardiovascular diseases, increased preference for minimally invasive procedures, and advancement in medical technology. Cardiovascular diseases are one of the leading causes of deaths worldwide, monitoring and  and interventional devices are, are highly in demand.

“Based on product type, the cardiac rhythm management devices segment to the second largest share”

Cardiac rhythm management (CRM) devices are designed to regulate and monitor the  hearts electrical activity, aiding to correct abnormal heart rhythms (arrhythmias). These devices are used  to treat diseases such as bradycardia , tachycardia, and heart failure by ensuring that the heart beats at a normal pace and rhythm. Leadless devices are more beneficial to the patients and enhance their safety. Therefore, its adoption rate is high as compared to traditional CRM devices, which often come with leads and thus prone to infections and mechanical failures. The leadless devices are also MRI-safe therefore highly adopted these days as MRI procedures are frequently required for patients suffering from other chronic conditions. Moreover, the growing older population and unhealthy lifestyle patterns have led to an increased number of cases for arrhythmia, further stimulating the growth in demand for CRM technologies. The adoption of these next-generation CRM devices by the population with the view of establishing itself in the market has resulted from technological innovation coupled with the prevalence of arrhythmia.

“The congestive heart failure segment is expected to hold a significant share, by indication segment in the cardiovascular devices market.”

Congestive heart failure is a chronic and progressive condition in which the heart cannot pump blood to meet the body's needs. Inefficiency may be due to several underlying heart conditions, such as coronary artery disease, high blood pressure, or cardiomyopathy, which weaken the heart muscle or impair its ability to fill properly. CHF affects millions of the world's population, and is increasingly prevalent due to  aging, sedentary lifestyle, and comorbidities such as obesity, hypertension, and diabetes. This condition has high medical demands. This requires advanced diagnostics and therapeutic solutions. Management of CHF requires various cardiovascular devices, that includes implantable cardiac defibrillator, CRT devices, LVADs, and remote monitoring systems. These devices improve survival and also enhance the quality of life by reducing hospitalization thereby, effectively managing symptoms.Therefore, healthcare providers are increasingly adopting innovative cardiovascular technologies which is further bolstered by favorable reimbursement policies and strong R&D investments. CHF is still a leading cause of cardiovascular morbidity and mortality, its increasing prevalence ensures steady demand for advanced cardiovascular devices.

“Based on end user, the ambulatory surgical centers account for the highest CAGR during the forecast period  in cardiovascular devices market.”

Interventional cardiology procedures using various devices such as stents are being done increasingly at ASCs as the length of time involved in various procedures has been shortening while the pressure on reducing healthcare costs yet effectively delivered still mounts. These centers afford a coordinated outpatient environment and are cheaper compared to in-hospital care; therefore, they attract the patient, as well as the practitioner. Today, due to less invasive techniques and even shorter recovery periods, procedures involving diagnostic angiography, PCIs, and stent placements are performed in these centers.

“North America accounted for the greatest share of the cardiovascular devices market.”

The cardiovascular devices market in North America is growing highly because of increased prevalence of cardiovascular diseases, an aged population. Heart disease is the needs immediate attention, and so this leads to a higher requirement for innovative and efficient intervention solutions. Key products in this area are ECG devices, Pacemakers, stents, catheters, and guidewires, increasing use in the major interventional procedures,and  which is angioplasty and regular monitoring, to improve outcomes as well as reduce recovery time. Besides, favorable government policies, increasing healthcare spending, and the increase of outpatient facilities are driving the market.

Key players in the cardiovascular devices market

Some of the prominent players operating in the cardiovascular devices market include include Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), Terumo Corporation (Japan), GE Healthcare Technologies, Inc. (US), Edward Lifesciences Corporation (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), B. Braun SE (Germany), Getinge AB (Sweden), Koninklijke Philips N.V. (Netherlands), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan),  MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.(US), LifeTech Scientific Corporation (China), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), OrbusNeich Medical Group Holdings Limited (China), BPL Medical Technologies (India), BiotroniK. (Germany),), W.L. Gore & Associates, Inc (US), Canon medical systems corporation (Japan),   Picard Medical Company (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.